Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Monogram Biosciences has signed an agreement with Avexa to be the exclusive provider of HIV resistance and tropism testing technology in support of Avexa's drug discovery and development programs.
Subscribe to our email newsletter
Avexa plans to use Monogram’s assays across its virology portfolio, including the Phase III program for its lead compound, apricitabine, an anti-HIV drug. Avexa also plans to use Monogram’s PhenoSense GT assay to select patients and optimize background therapy for trials involving approximately 2,000 patients, and to monitor response to drug treatment during the trials.
Julian Chick, Avexa’s CEO, said: “Monogram has an impressive portfolio of tests that we believe provide the accuracy and reliability that are necessary for studies that are intended to be submitted to the FDA and other regulatory agencies.”